Zynerba Pharmaceuticals (ZYNE) Peer Comparison

$1.30

$0.00 (0.00%)

As on 13-Oct-2023 09:30EDT

Market cap

$70 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.5

Div. Yield

0 %

Edit

	Zynerba Pharmaceuticals (ZYNE)	BiondVax Pharmaceuticals - ADR
Market cap ($ Mln)	70	5
Revenue ($ Mln)	--	2
Net Profit ($ Mln)	-37.01	17.22
Net Margin (%)	49,625.92	854.38
RoE (%)	-98.36	--
Price to Earnings	--	--
Price-To-Book	0.54	7.48

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Zynerba Pharmaceuticals (ZYNE)	BiondVax Pharmaceuticals - ADR
Operating Revenue	0.00	2.02
Cost of Revenue	0.00	0.00
Gross Profit	--	--
Operating Expenses	38.79	12.32
Operating Profit (EBIT)	-38.79	-12.32
Other Income	-0.07	0.00
Profit before Tax	-37.58	-1.21
Provision for Tax	-0.93	-18.59
Profit after Tax (Net Income)	-37.01	17.22
Minority Interest	0.00	0.00
Consolidated Profit	-19.45	3.75

Liabilities ($ Mln)

	Zynerba Pharmaceuticals (ZYNE)	BiondVax Pharmaceuticals - ADR
Shareholder's Funds	29.02	-7.11
Minority Interest	0.00	0.00
Non-Current Liabilities	0.00	25.12
Current Liabilities	11.46	1.89
Total Liabilities	55.52	27.07

Assets ($ Mln)

	Zynerba Pharmaceuticals (ZYNE)	BiondVax Pharmaceuticals - ADR
Non-Current Assets	1.18	12.13
Current Assets	39.29	7.77
Total Assets	55.52	27.07
Total Debt*	0.22	24.61
Net Current Assets	27.84	5.88

Cashflow ($ Mln)

	Zynerba Pharmaceuticals (ZYNE)	BiondVax Pharmaceuticals - ADR
Cash From Operating Activities	-23.03	-7.27
Cash Flow from Investing Activities	--	--
Cash from Financing Activities	6.01	6.78
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	Zynerba Pharmaceuticals (ZYNE)	BiondVax Pharmaceuticals - ADR
ROCE (%)	-59.00	-0.94
ROE (%)	-98.36	-4.92
ROA (%)	-57.62	26.32
EBIT Margin (%)	--	-618.44
Net Margin (%)	49,625.92	854.38
Cash Profit Margin (%)	--	0.00

Growth Ratios

	Zynerba Pharmaceuticals (ZYNE)	BiondVax Pharmaceuticals - ADR
Revenue Growth (%)	--	-26.64
EBIT Growth (%)	-5.13	62.64
Net Profit Growth (%)	2.64	141.72
EPS Growth (%)	16.03	--
Book Value Growth (%)	-58.14	--

Valuation Ratios

	Zynerba Pharmaceuticals (ZYNE)	BiondVax Pharmaceuticals - ADR
Price / Earnings	-0.69	--
Price / Book Value	0.52	--
Dividend Yield (%)	--	--
EV/EBITDA	0.76	-0.71
Market Cap ($ Cr)	--	--

Solvency Ratios

	Zynerba Pharmaceuticals (ZYNE)	BiondVax Pharmaceuticals - ADR
Debt to Equity	0.00	-3.28
Short term debt to equity ratio	0.01	-0.06
Current Ratio	3.43	4.12
Quick Ratio	3.31	4.12
Interest Coverage	-25.05	0.93

Operating Efficiency Ratios

	Zynerba Pharmaceuticals (ZYNE)	BiondVax Pharmaceuticals - ADR
Debtors to sales (%)	--	6.85
Asset Turnover	0.00	0.03
Receivable days	--	--
Inventory Days	--	--
Payable days	--	--
Cash Conversion Cycle	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly